NEW YORK, Sept. 19, 2022 /PRNewswire/ --The male hypogonadism market has been segmented by type (Klinefelter syndrome, Kallmann syndrome, and pituitary disorders) and geography (North America, Europe, Asia, and Rest of World (ROW)). North America will account for 37% of the market's growth during the forecast period. This growth is attributed to factors such as the significant increase in the prevalence of male hypogonadism. Moreover, market growth in this region will be faster than the growth of the market in other regions. The US and Canada are the key countries for the male hypogonadism market in North America.

Themale hypogonadism market size is estimated to grow by USD 684.95 mn from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 5.09% during the forecast period.

Technavio provides a comprehensive report summary describing the market size and forecast along with research methodology. The FREE sample reportis available in PDF format

Company Profiles

The male hypogonadism market report includes information on the product launches, sustainability, and prospects of leading vendors, including AbbVie Inc., Aytu BioPharma Inc., Bayer AG, Bio Techne Corp., Diurnal Group Plc, Eli Lilly and Co., Endo International Plc, Ferring B.V., IBSA Institute Biochimique SA, Lipocine Inc., Merck and Co. Inc., Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. The key offerings of some of these vendors are listed below:

Technavio's reports provide key strategic initiatives used by vendors, along with key news and the latest developments. View our FREE PDF Sample Report Now

Competitive Analysis

The competitive scenario provided in the male hypogonadism market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.

Market Dynamics

Factors such as an increase in the incidence of hypogonadism and the increasing awareness about male hypogonadism and its treatment options will be crucial in driving the growth of the market. However, the loss of patent exclusivities and increasing generic competition will restrict the market growth.

Technavio has identified key trends, drivers, and challenges in the market, which will help vendors improve their strategies to stay ahead of their competitors. View our FREE PDF Sample Report

Related Reports

Sexually Transmitted Diseases (STD) Treatment Market by Service and Geography - Forecast and Analysis 2022-2026: The sexually transmitted diseases (STD) treatment market share is expected to increase by USD 13.48 billion from 2021 to 2026.

Sexual Enhancement Supplements Market by Product and Geography - Forecast and Analysis 2022-2026: The sexual enhancement supplements market share is expected to increase by USD 801.29 million from 2021 to 2026.

Male Hypogonadism Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 5.09%

Market growth 2022-2026

USD 684.95 million

Market structure

Fragmented

YoY growth (%)

3.52

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 37%

Key consumer countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

AbbVie Inc., Aytu BioPharma Inc., Bayer AG, Bio Techne Corp., Diurnal Group Plc, Eli Lilly and Co., Endo International Plc, Ferring B.V., IBSA Institute Biochimique SA, Lipocine Inc., Merck and Co. Inc., Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Market Dynamics

Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse Health CareMarket Reports

Table of Contents

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Type

6 Customer Landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: media@technavio.com

Website: http://www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/male-hypogonadism-market-size-to-grow-by-usd-684-95-mn-abbvie-inc-and-bayer-ag-among-key-vendors---technavio-301626163.html

SOURCE Technavio

Read the original here:
Male Hypogonadism Market Size to Grow by USD 684.95 Mn, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio - Longview News-Journal

Comments are closed.